Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 4,808 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed No phase listed Observational

BREATHE: An Efficacy-implementation With Listening Sessions

NCT05045690
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Steroid-reducing Effects of Crisaborole

NCT03832010
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 28, 2026, 1:34 PM EDT
Completed No phase listed Observational

CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry

NCT03382678
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years and older
Enrollment
187 participants
Timeline
2018 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 28, 2026, 1:34 PM EDT
Terminated Not applicable Interventional

Anesthetic Effects in Mitochondrial Disease

NCT01001585
View directory record Official record
Conditions
Mitochondrial Disease
Interventions
sevoflurane
Drug
Lead sponsor
d sessler
Other
Eligibility
12 Months to 16 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

NCT05259917
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Placebo, KVD900 600 mg, KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

NCT04109313
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 28, 2026, 1:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889
View directory record Official record
Conditions
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Interventions
GB-0895 (SC), Placebo (SC)
Biological · Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Sustaining Smoking Cessation in Smokers With Kids With Asthma

NCT00862368
View directory record Official record
Conditions
Asthma, Smoking Cessation
Interventions
PAM, PAM-Enhanced/Asthma Counseling Phone Calls, Follow-Up Phone Calls - Child Wellness Topic
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
5
States / cities
Fall River, Massachusetts • Pawtucket, Rhode Island • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 28, 2026, 1:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Program for Caregivers Involved With Mental Health Services

NCT01872585
View directory record Official record
Conditions
Mental Illness
Interventions
Mentalization based therapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

NCT00657891
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Creighton University
Other
Eligibility
16 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 28, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

NCT00839124
View directory record Official record
Conditions
Asthma, Hypersensitivity
Interventions
Clinical Center Reference Endotoxin (CCRE)
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Results available

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

NCT00870584
View directory record Official record
Conditions
Persistent Allergic Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

NCT02475447
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 28, 2026, 1:34 PM EDT
Terminated Not applicable Interventional Results available

Dietary Interventions in Asthma Treatment: Sprouts Study

NCT01183923
View directory record Official record
Conditions
Asthma, Allergy
Interventions
Broccoli Sprouts, Alfalfa Sprouts
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 49 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

NCT03847896
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI
Combination Product · Drug · Other
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
4 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
73
States / cities
Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 28, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HealthSpark: Health Access for Children in Federally-Subsidized Child Care

NCT00339027
View directory record Official record
Conditions
Asthma, Obesity, ADHD
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
3 Years to 5 Years
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 28, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Exercise-induced Bronchospasm

NCT00701025
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 28, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Results available

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

NCT05288062
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Bone Marrow Biopsy, Dexamethasone, Lenalidomide, Pomalidomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 1:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.

NCT04843891
View directory record Official record
Conditions
Sarcoid, Cardiovascular Diseases, Cancer
Interventions
[64]Cu Macrin
Drug
Lead sponsor
Ralph Weissleder, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 28, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

NCT03747042
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Letrozole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 1:34 PM EDT